Treatment — Hantavirus

No specific antiviral treatment

There is no FDA-approved specific antiviral treatment for hantavirus infection. Ribavirin has been studied but has not demonstrated consistent efficacy for HPS in controlled trials. Early administration of ribavirin may have some benefit for HFRS in some studies, but evidence remains limited.

Supportive care

Treatment is entirely supportive and must be initiated early:

For HPS

ICU admission — patients deteriorate rapidly; continuous monitoring is essential
Mechanical ventilation — for respiratory failure from pulmonary edema
ECMO (extracorporeal membrane oxygenation) — for severe, refractory HPS; has improved survival in case series from 50% to nearly 70% when initiated early
Haemodynamic support — careful fluid management (avoid fluid overload), vasopressors for shock
Pulmonary artery catheterisation — to guide fluid management and cardiac output monitoring

For HFRS

Fluid management — critical during hypotensive and oliguric phases
Dialysis — for severe kidney injury with uraemia or fluid overload
Blood products — for significant haemorrhage
Electrolyte monitoring — particularly during the diuretic phase

No vaccine licensed in the Americas

No hantavirus vaccine is licensed in the Americas, Europe, or most of the world
China has licensed hantavirus vaccines (type I: Hantaan strain; type II: Seoul strain) since the 1990s; given to at-risk populations
South Korea has a licensed Hantaan virus vaccine; recommended for farmers and military personnel
Research into recombinant and DNA-based vaccines continues, but none are commercially available outside East Asia

Why early care matters

The single most important factor in hantavirus survival is early recognition and aggressive supportive care. Patients who reach an ICU before cardiovascular collapse have significantly better outcomes. ECMO availability has been associated with improved survival for severe HPS.

Sources

CDC. Treating HPS. CDC Treatment
Mertz GJ, et al. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 2004;39(9):1307-1313.
Raphael JH, et al. Extracorporeal membrane oxygenation for suspected hantavirus pulmonary syndrome. Crit Care 2012.
WHO. Hantavirus: Treatment and vaccines. WHO
Kruger DH, et al. Hantavirus prevention and control: a review. Curr Opin Virol 2019.